Autoimmune haemolytic anaemia and mefenamic acid therapy.
Three patients developed autoimmune haemolytic anaemia while being treated with mefenamic acid. In each case the autoimmune haemolytic anaemia was of the warm antibody gammaG type, and the antibodies had some rhesus specificity. All three patients recovered when the drug was withdrawn.Attempts to inhibit or enhance the activity of the antibody in vitro were unsuccessful.Direct antihuman globulin tests were made in.the red cells of 36 patients receiving long-term mefenamic acid therapy, but only one was found to be transitorily positive.
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000917:Antibody Formation; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D005260:Female; D006366:Heinz Bodies; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008528:Mefenamic Acid / Q000009:adverse effects; D008750:Methyldopa / Q000009:adverse effects; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy; D062367:ortho-Aminobenzoates / Q000009:adverse effects*
D000893:Anti-Inflammatory Agents; D062367:ortho-Aminobenzoates; D008528:Mefenamic Acid; D008750:Methyldopa